Immunocore (IMCR)
Immunocore Statistics
Share Statistics
Immunocore has 50.06M shares outstanding. The number of shares has increased by 0.6% in one year.
| Shares Outstanding | 50.06M |
| Shares Change (YoY) | 0.6% |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | 90.46% |
| Shares Floating | 44.2M |
| Failed to Deliver (FTD) Shares | 184 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 6.71M, so 13.42% of the outstanding shares have been sold short.
| Short Interest | 6.71M |
| Short % of Shares Out | 13.42% |
| Short % of Float | 13.79% |
| Short Ratio (days to cover) | 18.7 |
Valuation Ratios
The PE ratio is -28.87 and the forward PE ratio is -26.76. Immunocore's PEG ratio is 2.97.
| PE Ratio | -28.87 |
| Forward PE | -26.76 |
| PS Ratio | 4.75 |
| Forward PS | 1.6 |
| PB Ratio | 4.09 |
| P/FCF Ratio | 70.6 |
| PEG Ratio | 2.97 |
Enterprise Valuation
Immunocore has an Enterprise Value (EV) of 3,340.2B.
| EV / Earnings | -65382.17 |
| EV / Sales | 10767.75 |
| EV / EBITDA | -47404.65 |
| EV / EBIT | -47404.65 |
| EV / FCF | 159908.98 |
Financial Position
The company has a current ratio of 4.38, with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.38 |
| Quick Ratio | 4.36 |
| Debt / Equity | 0.12 |
| Total Debt / Capitalization | 10.36 |
| Cash Flow / Debt | 0.62 |
| Interest Coverage | 3.74 |
Financial Efficiency
Return on equity (ROE) is -0.14% and return on capital (ROIC) is -18.12%.
| Return on Equity (ROE) | -0.14% |
| Return on Assets (ROA) | -0.05% |
| Return on Capital (ROIC) | -18.12% |
| Revenue Per Employee | 629.21K |
| Profits Per Employee | -103.62K |
| Employee Count | 493 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 0.5 |
Taxes
| Income Tax | 1.85M |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by -56.37% in the last 52 weeks. The beta is 0.78, so Immunocore's price volatility has been higher than the market average.
| Beta | 0.78 |
| 52-Week Price Change | -56.37% |
| 50-Day Moving Average | 30.01 |
| 200-Day Moving Average | 34.88 |
| Relative Strength Index (RSI) | 45.55 |
| Average Volume (20 Days) | 260.25K |
Income Statement
In the last 12 months, Immunocore had revenue of 310.2M and earned -51.09M in profits. Earnings per share was -1.02.
| Revenue | 310.2M |
| Gross Profit | 307.47M |
| Operating Income | -70.46M |
| Net Income | -51.09M |
| EBITDA | -70.46M |
| EBIT | -70.46M |
| Earnings Per Share (EPS) | -1.02 |
Balance Sheet
The company has 455.73M in cash and 41.71M in debt, giving a net cash position of 414.02M.
| Cash & Cash Equivalents | 455.73M |
| Total Debt | 41.71M |
| Net Cash | 414.02M |
| Retained Earnings | -795.76M |
| Total Assets | 1.08B |
| Working Capital | 739.66M |
Cash Flow
In the last 12 months, operating cash flow was 26.06M and capital expenditures -5.17M, giving a free cash flow of 20.89M.
| Operating Cash Flow | 26.06M |
| Capital Expenditures | -5.17M |
| Free Cash Flow | 20.89M |
| FCF Per Share | 0.42 |
Margins
Gross margin is 99.12%, with operating and profit margins of -22.71% and -16.47%.
| Gross Margin | 99.12% |
| Operating Margin | -22.71% |
| Pretax Margin | -17.07% |
| Profit Margin | -16.47% |
| EBITDA Margin | -22.71% |
| EBIT Margin | -22.71% |
| FCF Margin | 6.73% |
Dividends & Yields
IMCR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3.47% |
| FCF Yield | 1.42% |
Analyst Forecast
The average price target for IMCR is $67, which is 127.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $67 |
| Price Target Difference | 127.8% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 1.21 |
| Piotroski F-Score | 2 |